昌吉割了包皮有影响吗(昌吉两个月了可以终止怀孕吗) (今日更新中)

The brunt of the storm may have passed, but North Carolina residents still face perilous conditions after record-setting snow walloped the state."With a mix of snow, ice and rain still coming down in some areas, conditions remain treacherous in many parts of our state," Gov. Roy Cooper said Monday.The storm, which pummeled the Southeast over the weekend, killed at least one person in North Carolina and grounded thousands of flights in the region, including more than 500 flights on Monday.PHOTOS: As southeastern winter storm fades, canceled flights and icy roads remainAbout 144,000 North Carolina households are still without power Monday morning, the governor said.In South Carolina, emergency officials said more than 56,000 power customers are without electricity Monday.With frigid conditions and widespread power outages, Cooper asked residents to check on vulnerable loved ones and the elderly, if possible. He said 15 emergency shelters have opened across North Carolina. 992

The combined jackpots for Mega Millions and Powerball?total more than 0 million right now, and it's possible that will surpass a combined billion.It's one of the highest combined totals ever for the two lottery games.The Mega Millions, with a current jackpot of 9 million, will be drawn at 11 p.m. Eastern today. The Powerball, which is at 4 million, is drawn on Saturday.The highest Mega Millions jackpot ever won was 6 million in 2012. It was split by winners in three states. The largest Powerball payout was 2 million in August 2018. 588

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis.The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago."What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid."How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing."We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis."I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid. 7224

The cold open of "Saturday Night Live" usually belongs to politics, but on Saturday night it belonged to moms.The mothers of cast members from the NBC variety show took over the beginning of Saturday's episode with many taking jabs at the show's political jokes.Kenan Thompson asked his mother if she liked the show and she responded, "I do, except for all the political stuff. We get it!"Mikey Day introduced his mother and reminded her of the time he was in a production of "The Crucible" in high school."You know, 'The Crucible' is a lot like that witch hunt against President Trump," Day's mother said before Day quickly ushered her off.The mother of the newcomer Luke Null asked, "Why doesn't 'SNL' talk about 'Crooked Hillary'?""Mom, I'm so new here," he said. "Please don't do this to me."As for Chris Redd's mother, she wondered why everyone is focused on Trump rather than "focusing on Jesus.""Okay, well, Jesus isn't president," Redd said."And that's the problem," his mother said back.And "Weekend Update" host Colin Jost asked his mom if she likes the political stuff on the show."I think Alec Baldwin does a great Trump impression," she said. "But why does it have to be so mean? Who writes that stuff?"Jost, who is also one of the show's head writers, hesitated and responded saying he didn't know blaming his "Weekend Update" co-host, Michael Che, who is also a head writer, for the jokes. 1412

The E.W. Scripps Company is a partner with The Associated Press and has been following guidance from their election desk on 2020 race updates.From Wednesday through Saturday, Joe Biden had a projected total of 264 Electoral College votes, six shy of the number needed to become president. As Election Day ground on into “election week,” it became increasingly clear that Biden would oust President Donald Trump from the White House. The question, rather, was where he would win, when it would happen and by how much, as late counted ballots in Nevada, Pennsylvania and Georgia continued to keep Biden in the lead and offered him multiple paths to victory. On Saturday, Biden captured the presidency when The Associated Press declared him the victor in his native Pennsylvania at 11:25 a.m. EST, garnering the state’s 20 electoral votes, which pushed him over the 270 electoral vote threshold needed to win. 914

来源：资阳报